Stay updated on Anetumab Ravtansine Multi-indication Clinical Trial
Sign up to get notified when there's something new on the Anetumab Ravtansine Multi-indication Clinical Trial page.

Latest updates to the Anetumab Ravtansine Multi-indication Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedThese changes are minor UI/text updates, including glossary toggle labels (Show glossary / Hide glossary) and footer/versioning text (Last Update Submitted that Met QC Criteria, No FEAR Act Data, Revision: v3.4.0). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check19 days agoChange DetectedRevision: v3.3.4 appears on the page, replacing the previous Revision: v3.3.3. This is a metadata version update and does not alter study details, results, or user-facing functionality.SummaryDifference0.0%

- Check48 days agoChange DetectedLocations section updated with a revised global list of study sites across multiple regions (e.g., U.S. states, Australia, Canada, Europe, and others). This corresponds to Revision: v3.3.3.SummaryDifference2%

- Check69 days agoChange DetectedRevision updated from v3.2.0 to v3.3.2 in the page footer. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check76 days agoChange DetectedRemoved the generic government funding status notice about data recency and operations. The study details on the page remain unchanged.SummaryDifference0.2%

- Check98 days agoChange DetectedCore study details, eligibility criteria, outcomes, and locations appear unchanged; the observed differences seem limited to cosmetic or layout changes. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

Stay in the know with updates to Anetumab Ravtansine Multi-indication Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Anetumab Ravtansine Multi-indication Clinical Trial page.